Iradimed Co (IRMD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Iradimed Co (IRMD) has a cash flow conversion efficiency ratio of 0.084x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($8.29 Million) by net assets ($98.51 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Iradimed Co fund operations to measure how many days the company can operate on defensive assets alone.
Iradimed Co - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Iradimed Co's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Iradimed Co Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Iradimed Co ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Waypoint REIT
AU:WPR
|
0.029x |
|
ZHEJIANG ASIA-PACIFIC MECHANICAL & ELECTRONIC CO LTD
SHE:002284
|
0.060x |
|
Weibo Corp
NASDAQ:WB
|
0.055x |
|
Suzhou Jinfu New Material Co
SHE:300128
|
-0.413x |
|
Atresmedia Corporación de Medios de Comunicación S.A.
MC:A3M
|
0.036x |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
0.397x |
|
Gibraltar Industries Inc
NASDAQ:ROCK
|
-0.047x |
|
Taboola
NASDAQ:TBLA
|
0.114x |
Annual Cash Flow Conversion Efficiency for Iradimed Co (2012–2025)
The table below shows the annual cash flow conversion efficiency of Iradimed Co from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Iradimed Co (IRMD) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $94.62 Million | $24.95 Million | 0.264x | -10.67% |
| 2024-12-31 | $86.82 Million | $25.62 Million | 0.295x | +56.55% |
| 2023-12-31 | $71.42 Million | $13.47 Million | 0.189x | +38.31% |
| 2022-12-31 | $73.67 Million | $10.04 Million | 0.136x | -12.61% |
| 2021-12-31 | $72.17 Million | $11.26 Million | 0.156x | +64.59% |
| 2020-12-31 | $61.38 Million | $5.82 Million | 0.095x | -48.58% |
| 2019-12-31 | $55.52 Million | $10.23 Million | 0.184x | +4.80% |
| 2018-12-31 | $41.95 Million | $7.38 Million | 0.176x | +69.52% |
| 2017-12-31 | $32.93 Million | $3.42 Million | 0.104x | -64.83% |
| 2016-12-31 | $31.89 Million | $9.41 Million | 0.295x | +23.14% |
| 2015-12-31 | $31.93 Million | $7.65 Million | 0.240x | +93.53% |
| 2014-12-31 | $20.89 Million | $2.59 Million | 0.124x | -54.48% |
| 2013-12-31 | $5.42 Million | $1.47 Million | 0.272x | -41.98% |
| 2012-12-31 | $3.22 Million | $1.51 Million | 0.469x | -- |
About Iradimed Co
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs moni… Read more